**Supplemental Materials**

**Impact of sarcopenia on long-term outcomes in hepatocellular carcinoma treated with** **trans-arterial radioembolization: A retrospective multi-center study**

Heechul Nam1,2, Hyun Yang1,2, Ho Soo Chun3, Han Ah Lee3, Joon Yeul Nam4, Jeong Won Jang1,2, Yeon Seok Seo5, Do Young Kim6, Yoon Jun Kim4, and Si Hyun Bae1,2\*

1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

2The Catholic University Liver Research Center, Seoul, Republic of Korea

3Departments of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea

4Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

5Department of Internal Medicine, Korea University Anam Hospital, Korea University College, Republic of Korea

6Department of Internal Medicine and Yonsei Liver Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

**Suppl. Table S1. Details of TARE procedure**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variables | Total  (n=347) | Non sarcopenic  (n = 221) | Sarcopenic  (n=126) | *P* value |
| Hepatopulmonart shunt (%) | 6.7 (4.8-9.7) | 6.7 (5.0-9.5) | 6.6 (4.4-10.3) | 0.780 |
| Type of microsphere |  |  |  |  |
| Resin | 212 (61.1%) | 145 (65.6%) | 67 (53.2%) | 0.022 |
| Glass | 135 (38.9%) | 79 (34.4%) | 59 (46.8%) |  |
| Administered activity (GBq) | 2.5 (1.7–3.4) | 2.5 (1.7–3.1) | 2.7 (1.6–3.8) | 0.210 |

Variables expressed as median (interquartile range) or n (%)

TARE, trans-arterial radioembolizati